CytoMed Therapeutics Management
Management criteria checks 2/4
CytoMed Therapeutics' CEO is Wee Kiat Tan, appointed in Feb 2019, has a tenure of 5.75 years. total yearly compensation is SGD116.30K, comprised of 98.3% salary and 1.7% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth €10.85K. The average tenure of the management team and the board of directors is 5.5 years and 1.6 years respectively.
Key information
Wee Kiat Tan
Chief executive officer
S$116.3k
Total compensation
| CEO salary percentage | 98.3% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.04% |
| Management average tenure | 5.5yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -S$3m |
| Mar 31 2024 | n/a | n/a | -S$4m |
| Dec 31 2023 | S$116k | S$114k | -S$4m |
| Sep 30 2023 | n/a | n/a | -S$4m |
| Jun 30 2023 | n/a | n/a | -S$4m |
| Mar 31 2023 | n/a | n/a | -S$4m |
| Dec 31 2022 | S$90k | S$87k | -S$3m |
| Sep 30 2022 | n/a | n/a | -S$3m |
| Jun 30 2022 | n/a | n/a | -S$2m |
| Mar 31 2022 | n/a | n/a | -S$2m |
| Dec 31 2021 | S$83k | S$83k | -S$2m |
| Sep 30 2021 | n/a | n/a | -S$2m |
| Jun 30 2021 | n/a | n/a | -S$2m |
| Mar 31 2021 | n/a | n/a | -S$2m |
| Dec 31 2020 | S$80k | S$80k | -S$2m |
Compensation vs Market: Wee Kiat's total compensation ($USD86.27K) is below average for companies of similar size in the German market ($USD471.14K).
Compensation vs Earnings: Wee Kiat's compensation has increased whilst the company is unprofitable.
CEO
Wee Kiat Tan (37 yo)
5.8yrs
Tenure
S$116,302
Compensation
Dr. Wee Kiat Tan, Ph D., serves as Chief Operating Officer of CytoMed Therapeutics Limited since February 2019 and also serves as its Director since April 18, 2023. He serves as Co-Chief Executive Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.7yrs | S$36.05k | 5.18% € 1.3m | |
| Co-CEO, COO & Director | 5.8yrs | S$116.30k | 0.043% € 10.8k | |
| Chief Scientific & Medical Officer and Director | 5.3yrs | S$118.43k | 5.11% € 1.3m | |
| Chief Financial Officer | 4.7yrs | no data | no data | |
| Chief Clinical Officer | 1.6yrs | no data | 0.80% € 200.8k | |
| Chief Corporate Officer | 6.4yrs | no data | no data |
5.5yrs
Average Tenure
37.5yo
Average Age
Experienced Management: F98's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.7yrs | S$36.05k | 5.18% € 1.3m | |
| Co-CEO, COO & Director | 1.6yrs | S$116.30k | 0.043% € 10.8k | |
| Chief Scientific & Medical Officer and Director | 1.6yrs | S$118.43k | 5.11% € 1.3m | |
| Independent Director | 1.6yrs | no data | no data | |
| Independent Director | 1.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Independent Director | 1.6yrs | no data | no data | |
| Independent Director | 1.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.6yrs | no data | 7.66% € 1.9m |
1.6yrs
Average Tenure
57yo
Average Age
Experienced Board: F98's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.